Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib

Fig. 4

MK-2206 sensitizes BRCA2 mutants to cisplatin and olaparib therapy. a 1. PEO1 and PEO4 cells were treated with various concentrations of cisplatin, MK-2206, or both in combination at a constant 1:1 ratio. After 72 h, MTS solution was added and absorbance read at 490 nm after 4 h. Data are means ± SD. 2. CI values were calculated for the drug combination of cisplatin and MK-2206 at each concentration. 3. PEO1 and PEO4 cells were treated with increasing doses of cisplatin in combination with 1 μM MK-2206 and caspase 3/7 activity determined after 72 h. b 1. Assay repeated for the combination of olaparib and MK-2206. 2. CI values for olaparib and MK-2206 3. a. Caspase 3/7 activity assay for olaparib and MK-2206 (1 μM) . Asterisks, p < 0.05 (Student’s t-test) b Caspase 3/7 activity assay for olaparib and MK-2206 (1, 3, and 6 μM)

Back to article page